SCHEMBL5540283

SCHEMBL5540283

FC(F)(F)Oc1ccccc1CCCNc1cc[c]cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.38
SLC6A3 Q01959 4/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
SLC6A2 P23975 2/20 0.36
VNN1 O95497 1/20 0.36
ALDH1A1 P00352 1/20 0.36
P2RX7 Q99572 1/20 0.35
MPO P05164 1/20 0.35
SLC22A12 Q96S37 3/20 0.34
KCNN3 Q9UGI6 1/20 0.34
BCHE P06276 2/20 0.34
ACHE P22303 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545445 0.92 SLC6A3 (0.40) DRD2SLC6A3MAPTMEN1HTT
SCHEMBL5535825 0.89 MAPT (0.34) DRD2SLC6A3MAPTMEN1HTT
SCHEMBL5535891 0.84 MAPT (0.50) MAPTMEN1HTTRAB9AKMT2A
SCHEMBL5544051 0.81 MEN1 (0.33) DRD2SLC6A3MAPTMEN1HTT
SCHEMBL5536714 0.78 HDAC1 (0.43) MAPTMEN1KMT2AHDAC3HDAC1
SCHEMBL5539839 0.76 MPO (0.49) MAPTMEN1KMT2AALDH1A1MPO
SCHEMBL5544585 0.76 ALDH1A1 (0.37) MAPTHDAC1ALDH1A1
SCHEMBL5546495 0.75 TAAR1 (0.46) SLC6A3MAPTRAB9ASLC6A2ALDH1A1
SCHEMBL5548214 0.75 ALDH1A1 (0.41) MAPTHDAC3HDAC1HDAC2HDAC6
SCHEMBL5539997 0.75 TAAR1 (0.42) MAPTMEN1HTTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DRD2 542/4885SLC6A3 1944/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.